Benefits
Lentinan as Cancer Adjunct (Japan)
Lentinan has been APPROVED PRESCRIPTION DRUG in Japan since 1985 as adjunct to chemotherapy for stomach cancer — given by injection. Multiple Japanese trials support extending survival in advanced gastric cancer. One of the most clinically-validated mushroom-derived compounds. Note: oral lentinan has limited absorption; injectable form drives evidence.
Cholesterol-Lowering (Eritadenine)
Shiitake contains ERITADENINE — a unique compound that lowers cholesterol via interference with phospholipid metabolism (specifically S-adenosyl methionine cycle). Animal studies show ~25% LDL reduction. Human evidence more modest.
Immune Modulation
Beta-glucans activate innate immunity — NK cells, macrophages, dendritic cells. Modest evidence for reduced respiratory infection severity.
Antioxidant Activity
Polyphenols, ergothioneine (sulfur amino acid antioxidant), and other compounds contribute to antioxidant capacity. Ergothioneine particularly notable as essentially mushroom-exclusive antioxidant.
Vitamin D Source (UV-Exposed)
Shiitake (and other mushrooms) contain ERGOSTEROL that converts to ERGOCALCIFEROL (vitamin D2) when exposed to UV light. UV-treated shiitake (commercially available) provides meaningful vitamin D2 — among few non-animal vitamin D sources.
Mechanism of action
Lentinan Immune Activation
Lentinan is a 1,3-beta-glucan that activates dectin-1 and complement receptor pathways on immune cells. Activates Th1 cellular immunity and NK cell function. Mechanism well-characterized — basis for cancer adjunct evidence.
Eritadenine Cholesterol Mechanism
Eritadenine (2(R),3(R)-dihydroxy-4-(9-adenyl)-butyric acid) interferes with hepatic phospholipid biosynthesis — alters lipoprotein metabolism. Unique mechanism distinct from statins or other cholesterol drugs.
Ergothioneine Antioxidant
Ergothioneine is a sulfur-containing amino acid found almost exclusively in mushrooms (and bacteria/fungi). Acts as cellular antioxidant; concentrated in tissues with high oxidative stress (kidney, liver, RBCs).
UV Conversion to Vitamin D2
Ergosterol in mushrooms converts to ergocalciferol (D2) when exposed to UV light. UV-exposed shiitake can provide significant D2 (manufacturers sun-dry or UV-treat for this purpose).
Clinical trials
Multiple Japanese RCTs and post-marketing studies of injectable lentinan (1-2 mg IV/week) as adjunct to chemotherapy in advanced gastric cancer.
Advanced gastric cancer patients.
Improved survival when added to chemotherapy. Approved by Japanese authorities as prescription adjunct cancer drug since 1985. CRITICAL: injectable formulation; oral lentinan has limited absorption.
Trial of whole shiitake mushroom consumption (5-10 g/day) for 4 weeks in healthy adults. Outcomes: immune cell function, inflammation markers.
Healthy adults.
Improved gamma delta T-cell and NK cell function, reduced inflammatory markers. Supports general immune-supportive role of dietary shiitake.
About this ingredient
Shiitake (Lentinula edodes) is one of the MOST WIDELY CONSUMED CULINARY MUSHROOMS globally — particularly in East Asian cuisine where it has been cultivated for >1,000 years. Also extensively studied medicinally — its purified polysaccharide LENTINAN was approved as PRESCRIPTION ANTI-CANCER DRUG in Japan in 1985 (one of few mushroom-derived compounds with prescription drug status).
KEY ACTIVE COMPOUNDS: (1) LENTINAN — purified 1,3-beta-glucan; primary medicinal compound; (2) ERITADENINE — unique cholesterol-lowering compound (rare in nature); (3) ERGOSTEROL — vitamin D2 precursor; UV converts to ergocalciferol; (4) ERGOTHIONEINE — sulfur-containing antioxidant amino acid; mushroom-exclusive; (5) Eritodenin — alternative spelling/compound. PRESCRIPTION FORM (JAPAN): injectable lentinan 1-2 mg/week as adjunct to chemo in advanced gastric cancer; established clinical evidence. ORAL SUPPLEMENTS: standardized extracts 1,000-3,000 mg/day; bioavailability limited; some products use AHCC (active hexose correlated compound) which is fermented mushroom mycelium extract overlapping with shiitake research.
EVIDENCE-BASED USES: (1) GASTRIC CANCER ADJUNCT (Japan, injectable lentinan); (2) Cholesterol modest reduction (eritadenine mechanism); (3) Immune support; (4) Vitamin D2 source (UV-exposed); (5) Antioxidant (ergothioneine); (6) Culinary food.
CRITICAL CAUTIONS: (1) SHIITAKE DERMATITIS / 'FLAGELLATE DERMATITIS' — RAW or UNDERCOOKED SHIITAKE causes characteristic linear 'whiplash' rash on body, especially trunk and extremities; well-documented; lentinan reaction; resolves spontaneously over 1-2 weeks; ALWAYS COOK SHIITAKE THOROUGHLY before eating; supplements typically avoid this issue; (2) ORAL LENTINAN — has LIMITED ABSORPTION; cancer evidence is from INJECTABLE form; oral supplements primarily provide whole mushroom or fermented mycelium benefits; do NOT expect injectable-level cancer adjunct effects from oral supplements; (3) AUTOIMMUNE DISEASE — immune activation theoretical concern; consult; (4) IMMUNOSUPPRESSION (transplant) — AVOID without medical supervision; (5) PREGNANCY/LACTATION — culinary use safe; supplemental forms limited safety data; AVOID concentrated extracts; (6) ALLERGIC REACTIONS — generally rare; cross-reactivity with mold allergies theoretical; (7) DOSE — 1,000-3,000 mg/day extract for general immune support; UV-treated shiitake for vitamin D2; (8) UV-EXPOSED PRODUCTS — provide significant vitamin D2; verify UV treatment if seeking D2 supplementation; non-UV-exposed mushrooms provide minimal D2; (9) ERGOTHIONEINE — increasingly studied as 'longevity vitamin'; mushrooms (especially shiitake, oyster, king bouletes) are primary dietary source; emerging research on cardiovascular and cognitive benefits; (10) CULINARY USE — incorporating shiitake into diet (cooked) provides nutritional and modest medicinal benefits with very low risk profile; foundational approach; (11) AHCC — separate product category; fermented shiitake mycelium; distinct evidence base for immune support and HPV; (12) ERITADENINE — unique cholesterol mechanism; modest human evidence; statins remain first-line for clinical hyperlipidemia.